238 related articles for article (PubMed ID: 26711503)
1. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
Tai BC; Chen ZJ; Machin D
Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
[TBL] [Abstract][Full Text] [Related]
2. Analysis and design of randomised clinical trials involving competing risks endpoints.
Tai BC; Wee J; Machin D
Trials; 2011 May; 12():127. PubMed ID: 21595883
[TBL] [Abstract][Full Text] [Related]
3. Sample size calculations in the presence of competing risks.
Latouche A; Porcher R
Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
[TBL] [Abstract][Full Text] [Related]
4. Analysing and interpreting competing risk data.
Pintilie M
Stat Med; 2007 Mar; 26(6):1360-7. PubMed ID: 16900575
[TBL] [Abstract][Full Text] [Related]
5. Proportional subdistribution hazards modeling offers a summary analysis, even if misspecified.
Grambauer N; Schumacher M; Beyersmann J
Stat Med; 2010 Mar; 29(7-8):875-84. PubMed ID: 20213713
[TBL] [Abstract][Full Text] [Related]
6. Modelling two cause-specific hazards of competing risks in one cumulative proportional odds model?
Ohneberg K; Schumacher M; Beyersmann J
Stat Med; 2017 Nov; 36(27):4353-4363. PubMed ID: 28833435
[TBL] [Abstract][Full Text] [Related]
7. Misspecified regression model for the subdistribution hazard of a competing risk.
Latouche A; Boisson V; Chevret S; Porcher R
Stat Med; 2007 Feb; 26(5):965-74. PubMed ID: 16755533
[TBL] [Abstract][Full Text] [Related]
8. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
Geskus RB
Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
[TBL] [Abstract][Full Text] [Related]
9. The importance of censoring in competing risks analysis of the subdistribution hazard.
Donoghoe MW; Gebski V
BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
[TBL] [Abstract][Full Text] [Related]
10. Dealing with competing risks: testing covariates and calculating sample size.
Pintilie M
Stat Med; 2002 Nov; 21(22):3317-24. PubMed ID: 12407674
[TBL] [Abstract][Full Text] [Related]
11. Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks.
Yang Q; Fung WK; Li G
Stat Med; 2018 Apr; 37(8):1389-1401. PubMed ID: 29282764
[TBL] [Abstract][Full Text] [Related]
12. The use and interpretation of competing risks regression models.
Dignam JJ; Zhang Q; Kocherginsky M
Clin Cancer Res; 2012 Apr; 18(8):2301-8. PubMed ID: 22282466
[TBL] [Abstract][Full Text] [Related]
13. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
Austin PC; Fine JP
Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
[TBL] [Abstract][Full Text] [Related]
14. Kidney Graft Failure and Patient Survival Modelling Based on Competing Risks Under Nonproportional Hazards.
Valenta Z; Skrabaka D; Owczarek AJ; Kolonko A; Król R; Więcek A; Ziaja J
Transplant Proc; 2022 May; 54(4):940-947. PubMed ID: 35450721
[TBL] [Abstract][Full Text] [Related]
15. Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models.
Mozumder SI; Rutherford MJ; Lambert PC
BMC Med Res Methodol; 2021 Mar; 21(1):52. PubMed ID: 33706711
[TBL] [Abstract][Full Text] [Related]
16. Sample size formula for proportional hazards modelling of competing risks.
Latouche A; Porcher R; Chevret S
Stat Med; 2004 Nov; 23(21):3263-74. PubMed ID: 15490425
[TBL] [Abstract][Full Text] [Related]
17. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
[TBL] [Abstract][Full Text] [Related]
18. Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes.
Poguntke I; Schumacher M; Beyersmann J; Wolkewitz M
BMC Med Res Methodol; 2018 Jul; 18(1):79. PubMed ID: 30012114
[TBL] [Abstract][Full Text] [Related]
19. On the relation between the cause-specific hazard and the subdistribution rate for competing risks data: The Fine-Gray model revisited.
Putter H; Schumacher M; van Houwelingen HC
Biom J; 2020 May; 62(3):790-807. PubMed ID: 32128860
[TBL] [Abstract][Full Text] [Related]
20. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
